CBST [NASD]
Cubist Pharmaceuticals Inc.
Index- P/E118.53 EPS (ttm)0.86 Insider Own10.60% Shs Outstand76.30M Perf Week0.99%
Market Cap7.78B Forward P/E52.55 EPS next Y1.94 Insider Trans-1.18% Shs Float75.88M Perf Month4.27%
Income- PEG5.93 EPS next Q0.30 Inst Own94.10% Short Float7.37% Perf Quarter51.38%
Sales1.16B P/S6.71 EPS this Y522.20% Inst Trans-7.16% Short Ratio2.18 Perf Half Y55.16%
Book/sh20.25 P/B5.03 EPS next Y70.20% ROA- Target Price98.50 Perf Year35.94%
Cash/sh- P/C- EPS next 5Y20.00% ROE- 52W Range58.50 - 101.99 Perf YTD1.28%
Dividend- P/FCF- EPS past 5Y-6.42% ROI- 52W High-0.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low74.26% ATR0.56
Employees873 Current Ratio- Sales Q/Q16.20% Oper. Margin- RSI (14)80.95 Volatility0.23% 0.32%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume3.26 Prev Close101.94
ShortableYes LT Debt/Eq- EarningsJan 22 AMC Payout- Avg Volume2.56M Price101.94
Recom3.00 SMA201.06% SMA5014.22% SMA20040.69% Volume0 Change0.00%
Dec-17-14Downgrade UBS Buy → Neutral $90 → $102
Dec-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $84 → $102
Dec-09-14Downgrade Mizuho Buy → Neutral $102
Dec-09-14Downgrade Gabelli & Co Buy → Sell
Jun-20-14Initiated Gabelli & Co Buy
Mar-12-14Reiterated Mizuho Buy $81 → $97
Mar-06-14Reiterated UBS Buy $75 → $90
Jan-24-14Reiterated Mizuho Buy $77 → $81
Jan-24-14Reiterated Aegis Capital Buy $70 → $85
Dec-20-13Reiterated RBC Capital Mkts Outperform $78 → $82
Oct-10-13Initiated Oppenheimer Outperform $81
Oct-09-13Upgrade Mizuho Neutral → Buy $50 → $77
Aug-01-13Upgrade Aegis Capital Hold → Buy $56 → $70
Jul-31-13Reiterated UBS Buy $61 → $70
May-21-13Upgrade Cantor Fitzgerald Sell → Hold $40 → $49
May-21-13Reiterated RBC Capital Mkts Outperform $53 → $63
May-03-13Initiated UBS Buy $61
Apr-03-13Downgrade Cantor Fitzgerald Hold → Sell $38 → $40
Feb-06-13Initiated Aegis Capital Hold $45
Jan-24-13Upgrade Cantor Fitzgerald Sell → Hold $37 → $38
Jan-29-15 02:27PM  When does the biotech party end? at CNBC
Jan-21-15 05:25PM  Merck Insiders' Planned Sales Hit $5.2 Million at Barrons.com
04:27PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delistin EDGAR Online
06:25AM  State Of The Union Lights Up Biotech Benzinga
Jan-20-15 05:45PM  Dana Holding Set to Join the S&P MidCap 400 PR Newswire
05:33PM  The 5 Best Dow Stocks So Far In 2015 Benzinga
Jan-18-15 08:20AM  Merck Is Top DJIA Stock in 2015 at 24/7 Wall St.
Jan-13-15 08:12AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:00AM  Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Business Wire
Jan-08-15 07:06AM  Teixobactin And iChip Promise Hope Against Antibiotic Resistance at Forbes
Jan-02-15 07:33AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Dec-31-14 08:59AM  19 Lesser-Known Biotech Stocks With Robust Drug Pipelines Benzinga
Dec-24-14 09:23AM  Cramer's Mad Dash: Pharma movers CNBC
Dec-23-14 10:03AM  Jim Cramer on the Markets: Some Stocks You Just Can't Ignore at TheStreet
Dec-22-14 11:44AM  Merck Finally Gets Some Good News on Cubist at The Wall Street Journal
09:03AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:20AM  Approval of new antibiotic by Cubist to help in $100 trillion global fight at American City Business Journals
Dec-19-14 07:06PM  [$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa at The Wall Street Journal
06:30PM  FDA Approves Second Cubist Antibiotic Of 2014 at Forbes
06:08PM  Cubist Announces FDA Approval of New Antibiotic ZERBAXA (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections Business Wire
06:07PM  FDA approves Cubists' drug for antibiotic-resistant bacteria Reuters
01:17PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefit Pl EDGAR Online
08:00AM  Merck Begins Tender Offer to Acquire Cubist Business Wire
Dec-18-14 01:16PM  $100 trillion Superbugs threat CNBC
11:54AM  Tetraphase Jumps As 'Superbug' Drug Scores In Trial at Investor's Business Daily
Dec-17-14 11:06AM  Cubist Pharma downgraded by UBS Briefing.com
09:13AM  Pharmalot, Pharmalittle: We're Reading About UCB, FDA, Biotechs and Much More!! at The Wall Street Journal
Dec-15-14 07:07PM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company PR Newswire
Dec-13-14 12:46AM  Charting the Market at Barrons.com
Dec-12-14 05:07PM  SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
10:19AM  CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co. Business Wire
Dec-11-14 02:22PM  CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
12:45PM  Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research Inc., Conn's, Inc., Cubist Pharmaceuticals, Inc., Hawaiian Electric Industries, Inc., and Heritage Financial Group, Inc. PR Newswire
Dec-10-14 03:30PM  Merck-Cubist Deal On Despite Patent Setback, Shares Fall Zacks
12:51PM  CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. Business Wire
09:44AM  Merck's $8.4 Billion Deal for Cubist Looks $2 Billion Too Expensive Now at The Wall Street Journal
08:50AM  Cubist sales force seen as potential boon for Merck intestinal drug Reuters
Dec-09-14 09:31PM  Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests PR Newswire
06:52PM  Cubist sales force seen as potential boon for Merck intestinal drug Reuters
06:00PM  Cramer views market like NFL CNBC
04:49PM  Merck Reaffirms Commitment to Cubist Deal at The Wall Street Journal
03:30PM  Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck Zacks
12:14PM  Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement Benzinga
11:51AM  Cubist Pharmaceutical (CBST) Stock Declines Today Following Patent Rejection at TheStreet
11:49AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. -- CBST PR Newswire
11:27AM  Merck-Cubist Deal Is On Despite Patent Setback at Investor's Business Daily
11:17AM  Merck & Cubist: Well, It Seemed Like a Good Idea at the Time at Barrons.com
11:09AM  Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc Benzinga
10:59AM  Jim Cramer on the Stock Market: Thoughts on Merck's Deal for Cubist at TheStreet
10:53AM  Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc. PR Newswire
10:27AM  Merck committed to Cubist after patent losses AP
09:30AM  Merck & Co. Under Pressure Following Patent Ruling Benzinga
09:27AM  Stocks to Watch: Conn's, AutoZone, Abercrombie & Fitch at The Wall Street Journal
08:59AM  Merck says still plans Cubist purchase, despite patent setback Reuters
08:50AM  After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? at 24/7 Wall St.
08:30AM  Michigans Gordon, Bloombergs McCracken on Merck Deal (Audio) at Bloomberg
07:58AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:45AM  Biotech ETFs in Focus on Cubist Takeover Deal Zacks
12:29AM  Merck to Buy Antibiotics Maker for $8.4 Billion at The Wall Street Journal
Dec-08-14 09:46PM  Merck to Buy Cubist for $8.4 Billion at The Wall Street Journal +35.29%
08:00PM  Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc. PR Newswire
07:01PM  Cramer Remix: 3 stocks with long-term potential at CNBC
06:52PM  Cubist Comments on CUBICIN Patent Litigation Business Wire
06:49PM  Antibiotics Worth A Shot: Merck To Purchase Cubist Investor's Business Daily
06:48PM  Cramer's personal connection to Merck acquisition at CNBC
06:30PM  Merck dives into 'superbug' chase with Cubist AP
06:09PM  Merck to buy Cubist Pharmaceuticals for $8.4 billion at Los Angeles Times
05:39PM  Court rules Hospira can launch generic Cubicin in 2016 Reuters
05:10PM  Merck's $9.5B Purchase Of Cubist Likely a Winner at Barrons.com
05:09PM  Merck Announces Acquisition of Cubist; Hedge Funds Celebrate Yahoo Finance Blogs
04:24PM  Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low at TheStreet
04:02PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri EDGAR Online
03:30PM  Stocks Recover From Session Lows Though Oil Prices Continue to Hurt at TheStreet
03:17PM  Why Jim Cramer Likes Merck's Acquisition of Cubist Pharmaceuticals (CBST) at TheStreet
02:49PM  SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
02:46PM  Merck Triggers The Race to Replace Cubist at Forbes
02:16PM  Merck & Co., Inc. -- Moody's affirms Merck & Co.'s ratings; outlook stable at Moody's
02:14PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. Business Wire
02:05PM  Merck buying Cubist Pharmaceuticals for $8.4B at USA TODAY
01:46PM  US STOCKS-Wall St falls with energy shares; global data disappoints Reuters
01:23PM  Merck/Cubist: pony up at Financial Times
01:20PM  Nasdaq stocks posting largest percentage increases AP
01:01PM  $9.5 billion blockbuster drug deal CNBC
01:00PM  Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences, Cempra, Isis Pharmaceuticals Benzinga
12:56PM  Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump Benzinga
12:54PM  Cubist options unusually active before Merck deal Reuters
12:00PM  Stocks Mostly Lower as Global Growth Worries Weigh Morningstar
11:57AM  CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck & Co., Inc. Business Wire
11:53AM  McDonald's nose dives, Merck's $8.4B Cubist deal & Gross juices Janus Yahoo Finance
11:48AM  Merck Acquiring Cubist, Focusing On Hospital Care at Investor's Business Daily
11:36AM  Merck to Buy Cubist Pharmaceuticals in $9.5 Billion Deal at TheStreet
11:26AM  Best Biotech ETFs Gets a Lift From Mercks Cubist Buy ETF Trends
11:26AM  Best Biotech ETF Gets a Lift From Mercks Cubist Buy ETF Trends
11:13AM  US STOCKS-Wall St flat after Japan, China data; biotechs climb Reuters
11:04AM  Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff at TheStreet
10:45AM  CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
10:40AM  Stocks sluggish as Dow eyes 18,000 at USA TODAY
10:32AM  Block & Leviton LLP Investigates Cubist Pharmaceuticals Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Proposed Acquisition by Merck & Co. PR Newswire
10:30AM  Cubist Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Merck PR Newswire
10:23AM  Mon., Dec. 8: Watch McDonald's Stock at MarketWatch
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DesRosier ThomasEVP, Chief Legal OfficerDec 29Option Exercise45.9017,975825,05319,797Dec 31 04:04 PM
VINK PATRICK V.J.J.SVP & GM, International Bus.Oct 15Option Exercise0.002,12505,496Oct 16 04:00 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerOct 01Option Exercise65.3948,1253,146,71175,723Oct 02 04:07 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerOct 01Sale65.3948,1253,146,71027,598Oct 02 04:07 PM
STEA GREGORYSVP, Commercial OperationsAug 19Option Exercise37.3838,3261,432,79856,462Aug 20 04:11 PM
STEA GREGORYSVP, Commercial OperationsAug 19Sale65.8838,3262,524,85218,136Aug 20 04:11 PM
Hutson Nancy JDirectorAug 18Option Exercise0.009,000014,951Aug 18 04:06 PM
Hutson Nancy JDirectorAug 18Sale65.009,000585,0005,951Aug 18 04:06 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerAug 18Sale63.6840926,0436,132Aug 18 04:03 PM
PEREZ ROBERT JPresident & COOAug 18Sale63.681,00363,86647,325Aug 18 04:05 PM
PEREZ ROBERT JPresident & COOAug 15Option Exercise0.002,125048,328Aug 18 04:05 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerAug 15Option Exercise0.001,25006,541Aug 18 04:03 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJul 28Option Exercise25.2340,6251,024,96968,223Jul 29 04:01 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJul 28Sale61.5740,6252,501,10427,598Jul 29 04:01 PM
MOULDER LEON O JRDirectorJun 03Option Exercise0.001,104011,101Jun 05 03:11 PM
Soeters Martinus HermanusDirectorJun 03Option Exercise0.001,104010,397Jun 05 03:12 PM
Lawton Alison FrancesDirectorJun 03Option Exercise0.001,10404,717Jun 05 03:09 PM
HENNEY JANE E MDDirectorJun 03Option Exercise0.001,10404,644Jun 05 03:08 PM
CORRIGAN MARKDirectorJun 03Option Exercise0.001,10407,501Jun 05 03:07 PM
BATE KENNETHDirectorJun 03Option Exercise0.001,70109,615Jun 05 03:06 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 15Option Exercise16.7615,125253,49542,723May 15 02:43 PM
STEA GREGORYSVP, Commercial OperationsMay 15Sale67.5087559,06318,136May 15 02:46 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 15Sale67.8216,3401,108,24027,598May 15 02:43 PM
PEREZ ROBERT JPresident & COOMay 15Sale67.501,518102,46545,869May 15 02:44 PM
BONNEY MICHAEL WChief Executive OfficerMay 15Sale67.503,036204,930175,859May 15 02:42 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 14Option Exercise0.002,500028,813May 15 02:43 PM
BONNEY MICHAEL WChief Executive OfficerMay 14Option Exercise0.006,2500178,895May 15 02:42 PM
PEREZ ROBERT JPresident & COOMay 14Option Exercise0.003,125047,387May 15 02:44 PM
STEA GREGORYSVP, Commercial OperationsMay 14Option Exercise0.001,800019,011May 15 02:46 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerMay 14Sale69.0049934,4315,291May 14 04:13 PM
BONNEY MICHAEL WChief Executive OfficerMay 14Sale69.003,840264,960172,645May 14 04:10 PM
PEREZ ROBERT JPresident & COOMay 14Sale69.002,400165,60044,262May 14 04:12 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 14Sale69.001,680115,92026,313May 14 04:11 PM
STEA GREGORYSVP, Commercial OperationsMay 14Sale69.0086559,68517,211May 14 04:13 PM
STEA GREGORYSVP, Commercial OperationsMay 13Option Exercise0.001,800018,076May 14 04:13 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 13Option Exercise0.003,500027,993May 14 04:11 PM
PEREZ ROBERT JPresident & COOMay 13Option Exercise0.005,000046,662May 14 04:12 PM
BONNEY MICHAEL WChief Executive OfficerMay 13Option Exercise0.008,0000176,485May 14 04:10 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerMay 13Option Exercise0.001,50005,790May 14 04:13 PM
DesRosier ThomasEVP, Chief LegalApr 16Sale64.0076849,1521,609Apr 16 04:44 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerApr 16Sale64.0044128,2244,290Apr 16 04:45 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerApr 15Option Exercise0.001,36104,731Apr 16 04:45 PM
DesRosier ThomasEVP, Chief LegalApr 15Option Exercise0.002,37702,377Apr 16 04:44 PM
STEA GREGORYSVP, Commercial OperationsMar 06Option Exercise42.094,600193,61420,876Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 06Sale79.994,600367,95416,276Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 05Option Exercise36.7515,289561,92828,665Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 05Sale79.6715,2891,218,03916,276Mar 06 04:38 PM
PEREZ ROBERT JPresident & COOFeb 27Option Exercise19.5130,000585,30071,662Feb 28 04:04 PM
BONNEY MICHAEL WChief Executive OfficerFeb 27Option Exercise10.84100,0001,084,000268,485Feb 28 04:06 PM
CORRIGAN MARKDirectorFeb 27Option Exercise18.225,00091,10010,498Feb 28 02:06 PM
BONNEY MICHAEL WChief Executive OfficerFeb 27Sale81.25100,0008,125,130168,485Feb 28 04:06 PM
PEREZ ROBERT JPresident & COOFeb 27Sale80.1830,0002,405,43941,662Feb 28 04:04 PM
CORRIGAN MARKDirectorFeb 27Sale80.005,000400,0005,498Feb 28 02:06 PM
BONNEY MICHAEL WChief Executive OfficerFeb 20Sale75.603,112235,268168,485Feb 21 08:06 AM
BONNEY MICHAEL WChief Executive OfficerFeb 19Option Exercise0.009,5000171,597Feb 21 08:06 AM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 18Sale75.002,645198,37524,493Feb 19 03:37 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 18Sale75.0055541,6253,370Feb 19 03:36 PM
PEREZ ROBERT JPresident & COOFeb 18Sale75.003,504262,80041,662Feb 19 03:39 PM
STEA GREGORYSVP, Commercial OperationsFeb 18Sale75.0098573,87516,276Feb 19 03:40 PM
STEA GREGORYSVP, Commercial OperationsFeb 16Option Exercise0.001,600017,261Feb 19 03:40 PM
PEREZ ROBERT JPresident & COOFeb 16Option Exercise0.005,000045,166Feb 19 03:39 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 16Option Exercise0.0083303,925Feb 19 03:36 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 16Option Exercise0.003,750027,138Feb 19 03:37 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 15Option Exercise0.001,953023,388Feb 19 03:37 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 15Option Exercise0.0075103,092Feb 19 03:36 PM
VINK PATRICK V.J.J.SVP & GM, International Bus.Feb 15Option Exercise0.001,24603,371Feb 19 03:35 PM
PEREZ ROBERT JPresident & COOFeb 15Option Exercise0.002,554040,166Feb 19 03:39 PM
STEA GREGORYSVP, Commercial OperationsFeb 15Option Exercise0.001,472015,661Feb 19 03:40 PM
BATE KENNETHDirectorFeb 03Option Exercise22.716,250141,93814,164Feb 04 12:22 PM
BATE KENNETHDirectorFeb 03Sale72.156,250450,9527,914Feb 04 12:22 PM